Full Length Research Paper
References
| Banez OM, Saduvala N, Oster AM, Kim D, Kline R, Pearson M, Hernandez AL, Hall HI (2014). Transmitted HIV-1 drug resistance among men who have sex with men - 11 U.S jurisdictions, 2008-2011. Available at: http://www.croiconference.org/sites/all/abstracts/579.pdf | ||||
|
Bellecave P, Recordon-Pinson P, Papuchon J, Vandenhende MA, Reigadas S, Tauzin B, Fleury H (2013). Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals. AIDS Res. Hum. Retroviruses 30(2):170-3. Crossref |
||||
|
Boyd AC, Herzberg EM, Marshall MM, Lamparello NA, De Leon MA, Porter A, Evans CH, Doshi S, Shahkolahi A, Dekker D, Relf MV (2008). Antiretroviral drug resistance among treatment-naive HIV-1-infected persons in Washington, D.C. AIDS Patient Care STDS 22(6):445-448. Crossref |
||||
|
Castor D, Low A, Evering T, Karmon S, Davis B, Figueroa A, LaMar M, Garmon D, Mehandru S, Markowitz M (2012). Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J. Acquir. Immune Defic. Syndr. 61(1):1-8. Crossref |
||||
|
Centers for Disease Control and Prevention (CDC) (2013). Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for injecting drug users. MMWR 62(23):463. Pubmed |
||||
| Centers for Disease Control and Prevention (2011). HIV surveillance report, 2011, vol. 23. | ||||
| District of Columbia HIV/AIDS, hepatitis, STD, and TB (HAHSTA) (2010). Annual report Washington, DC. | ||||
| Gajjala J, Farhat F, Daftary M, Mody V, Lee J, Crist M (2008). Antiretroviral drug-resistance mutations and resistance to antiretrovirals among patients with newly diagnosed HIV - experiences in inner-city hospital clinic. AIDS 2008 - XVII International AIDS Conference: Abstract no. TUPE0037. | ||||
|
Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellmann N, Bates M, Hirsch MS, Walker BD (2003). Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin. Infect. Dis. 37(12):1693-1698. Crossref |
||||
|
Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO (2002). Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288(2):181-188. Crossref |
||||
|
Huaman MA, Aguilar J, Baxa D, Golembieski A, Brar I, Markowitz N (2011). Late presentation and transmitted drug resistance mutations in new HIV-1 diagnoses in Detroit. Int. J. Infect. Dis. 15(11):e764-8. Crossref |
||||
|
Hurt CB, McCoy SI, Kuruc J, Nelson JA, Kerkau M, Fiscus S, McGee K, Sebastian J, Leone P, Pilcher C, Hicks C, Eron J (2009). Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007. Antivir. Ther. 14(5):673-678. Pubmed |
||||
|
Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, Craig C, Smith A, Bennett DE, Monsour M, Sandstrom P, Lanier ER, Heneine W (2008). Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med. 5(7):e158. Crossref |
||||
|
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD (2002). Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347(6):385-94. Crossref |
||||
|
Little SJ, Daar ES, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD (1999). Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282(12):1142-1149. Crossref |
||||
|
Little SJ, Frost SD, Wong JK, Smith DM, Pond SL, Ignacio CC, Parkin NT, Petropoulos CJ, Richman DD (2008). Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J. Virol. 82(11):5510-5518. Crossref |
||||
|
MacVeigh MS, Kosmetatos MK, McDonald JE, Reeder JL, Parrish DA, Young TP (2013). Prevalence of drug-resistant HIV type 1 at the time of initiation of antiretroviral therapy in Portland, Oregon. AIDS Res. Hum. Retroviruses 29(2):337-342. Pubmed |
||||
| Nybo E, Barrere B (2012). HIV prevalence estimates from the Demographic and Health Surveys. ICF International, Calverton, Maryland, USA. Available at: http://dhsprogram.com/pubs/pdf/OD65/OD65.pdf | ||||
|
Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, Gifford R, Nielsen C, Pedersen C, Balotta C, Rezza G, Ortiz M, de Mendoza C, Kücherer C, Poggensee G, Gill J, Porter K (2006). The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 20(1):21-28. Crossref |
||||
|
Readhead AC, Gordon DE, Wang Z, Anderson BJ, Brousseau KS, Kouznetsova MA, Forgione LA, Smith LC, Torian LV (2012). Transmitted antiretroviral drug resistance in New York State, 2006-2008: Results from a new surveillance system. PLoS One 7(8):e40533. Crossref |
||||
|
Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, Shaefer M (2007). Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities. HIV Clin. Trials 8(1):1-8. Crossref |
||||
| Ross L, Dix L, Wine B, Vavro C, Horton J, Pappa K (2008). Changes in regional prevalence, clade, and epidemiology of HIV-1 drug resistance mutations and clade among antiviral therapy-naive patients in the United States from 2000-2007. Antivir. Ther. 13(4):160. | ||||
|
Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA (2005). Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin. Infect. Dis. 41(9):1316-1323. Crossref |
||||
|
Shet A, Berry L, Mohri H, Mehandru S, Chung C, Kim A, Jean-Pierre P, Hogan C, Simon V, Boden D, Markowitz M (2006). Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: A decade of experience. J. Acquir. Immune Defic. Syndr. 41(4):439-446. Crossref |
||||
|
Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, Parkin N, Boden D, Markowitz M (2002). Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16(11):1511-1519. Crossref |
||||
|
Taniguchi T, Nurutdinova D, Grubb JR, Önen NF, Shacham E, Donovan M, Overton ET (2012). Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res. Hum. Retroviruses 28(3):259-264. Crossref |
||||
|
Truong HM, Kellogg TA, McFarland W, Louie B, Klausner JD, Philip SS, Grant RM (2011). Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One 6(10):e25281. Crossref |
||||
|
Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM Jr, LaLota M, Dickinson G, Schwarcz S, Torian L, Wendell D, Paul S, Goza GA, Ruiz J, Boyett B, Kaplan JE (2004).The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189(12):2174-80. Crossref |
||||
|
Weinstock H, Respess R, Heneine W, Petropoulos CJ, Hellmann NS, Luo CC, Pau CP, Woods T, Gwinn M, Kaplan J (2000). Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J. Infect. Dis. 182(1):330-3. Crossref |
||||
|
Wheeler WH, Ziebell RA, Zabina H, Pieniazek D, Prejean J, Bodnar UR, Mahle KC, Heneine W, Johnson JA, Hall HI (2010). Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS 24(8):1203-12. Crossref |
||||
|
Wittkop L, Günthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, Kücherer C, Obel N, von Wyl V, Masquelier B, Stephan C, Torti C, Antinori A, García F, Judd A, Porter K, Thiébaut R, Castro H, van Sighem AI, Colin C, Kjaer J, Lundgren JD, Paredes R, Pozniak A, Clotet B, Phillips A, Pillay D, Chêne G (2011). Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect. Dis. 11(5):363-371. Crossref |
||||
|
Yanik EL, Napravnik S, Hurt CB, Dennis A, Quinlivan EB, Sebastian J, Kuruc JD, Eron JJ (2012). Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J. Acquir. Immune Defic. Syndr. 61(2):258-262. Crossref |
||||
| Yerly ST, Junier E, Boffi H, Guenthard F, Zdobnov E, Hirschel B, Kaiser L (2008). Drug resistance in newly HIV diagnosed individuals: Transmission rate, clusters and persistence. Antivir. Ther. 12(Suppl 3):A167. | ||||
|
Youmans E, Tripathi A, Albrecht H, Gibson JJ, Duffus WA (2011). Transmitted antiretroviral drug resistance in individuals with newly diagnosed HIV infection: South Carolina 2005-2009. South Med. J. 104(2):95-101. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
